Shanghai Henlius Biotech, Inc. (2696.HK) and Organon today announced that the European Medicines Agency (EMA) has validated the marketing authorization application (MAA) for HLX11, an investigational ...

Pertuzumab has been approved in various countries and regions in combination with trastuzumab and chemotherapy ... manufacturing, packaging, and operations; difficulties developing and sustaining ...

Enveric Biosciences ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, ...

AZ’s investment comes as the company is seeing strong sales of HER2-targeted ADC Enhertu (trastuzumab deruxtecan ... for a significant financial aid package to support the projects.

Cancer treatments have revolutionized survival outcomes, yet they come with unintended consequences, particularly affecting ...

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

Pertuzumab has been approved in various countries and regions in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced ...

Tailored Approaches in the Treatment of Patients With Colorectal Cancer Harboring Tropomyosin Receptor Kinase Fusion and Microsatellite Instability-High: A Case Report and Literature Review A ...

The Boards of Directors of the Cohen & Steers Closed-End Funds announced today the monthly distributions for April, May and June 2025, as summarized in the charts below: Seegene Inc., a global ...

Copyright 2025 BBC. All rights reserved. The BBC is not responsible for the content of external sites. Read about our approach to external linking.